CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to treat participants with the combination of CPI-613 (the study
drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and
effective for participants with localized and unresectable pancreatic cancer. This study is
specifically for participants who have a pancreatic cancer that is localized and not
considered resectable or removable by a surgeon, without additional treatment.